Stifel lowered the firm’s price target on Cue Biopharma to $4 from $8 and keeps a Buy rating on the shares following management’s pausing of CUE-101/102 development to emphasize an increased focus on autoimmune disease. The firm’s target price change mostly represents delayed CUE-101 commercialization timelines and revised non-dilutive and dilutive financing assumptions, partially offset by lower operating expense assumptions, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUE:
- Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Options Volatility and Implied Earnings Moves Today, August 19, 2024
- Cue Biopharma price target lowered to $3 from $8 at Piper Sandler
- Cue Biopharma price target lowered to $2 from $15 at JMP Securities
- Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations